

# Cost of a population-based programme of chest x-ray screening for lung cancer

L. Dominioni<sup>1</sup>, N. Rotolo<sup>1</sup>, A. Poli<sup>2</sup>, M. Castiglioni<sup>1</sup>, M. Mangini<sup>3</sup>, M. Spagnoletti<sup>1</sup>, M. Paolucci<sup>4</sup>, A. Paddeu<sup>5</sup>, W. Mantovani<sup>6</sup>, A. Zanini<sup>7</sup>, A. Imperatori<sup>1</sup>

**ABSTRACT:** *Cost of a population-based programme of chest x-ray screening for lung cancer. L. Dominioni, N. Rotolo, A. Poli, M. Castiglioni, M. Mangini, M. Spagnoletti, M. Paolucci, A. Paddeu, W. Mantovani, A. Zanini, A. Imperatori.*

**Background.** After the implementation of a population-based programme of chest x-ray (CXR) screening on smokers in Varese, Italy, lung cancer (LC) mortality was significantly reduced. Analysis of the incremental costs due to this type of screening programme is needed to evaluate its economic impact on the healthcare system.

**Methods.** In July 1997 a population-based cohort, consisting of all high-risk smokers (n=5,815) identified among 60,000 adult residents from the Varese province, was invited to a LC screening programme (an annual CXR for five years) in a general practice setting, and was observed through 2006. Invitees received National Health Service (NHS) usual care, with the addition of CXRs in screening participants. At the end of observation, among the 245 LCs diagnosed in the entire screening-invited co-

hort the observed LC deaths were 38 fewer than expected. To estimate the incremental direct cost due to screening in the invited cohort for the period July 1997-2006, we compared the direct cost of screening administration, CXR screens and LC management in the invited cohort and in the uninvited and unscreened controls in NHS usual care setting.

**Results.** Over the 9.5 years, the total incremental direct healthcare costs (including screening organization/administration, CXR screens, additional procedures prompted by false-positive tests, overdiagnosed LCs) were estimated to range from € 607,440 to € 618,370 (in euros as of 2012), equating to between € 15,985- € 16,273 per patient out of the 38 LC deaths averted.

**Conclusions.** In a general practice setting, the incremental cost for a CXR screening programme targeted at all high-risk smokers in a population of 60,000 adults was estimated to be about € 65,000 per annum, approx. € 16,000 for each LC death averted.

*Monaldi Arch Chest Dis 2013; 79: 2, 67-72.*

**Keywords:** Lung cancer screening, Economic evaluation, Chest radiography, Chest x-ray, Population-based, Cost-effectiveness.

<sup>1</sup> Center for Thoracic Surgery, University of Insubria, Ospedale di Circolo di Varese;

<sup>2</sup> Department of Public and Community Medicine, University of Verona;

<sup>3</sup> Department of Radiology, University of Insubria, Ospedale di Circolo di Varese;

<sup>4</sup> Department of Radiology, Ospedale S. Antonio Abate, Gallarate;

<sup>5</sup> Respiratory Care Unit, Ospedale S. Anna, San Fermo della Battaglia, Como;

<sup>6</sup> Department of Prevention, Public Health Trust, Trento;

<sup>7</sup> Division of Pneumology, Fondazione F. Maugeri, IRCCS Rehabilitation Institute of Tradate, Italy.

Correspondence: Lorenzo Dominioni, Center for Thoracic Surgery, University of Insubria, Ospedale di Circolo, Via Guicciardini 9, 21100 Varese, Italy; e-mail: [lorenzo.dominioni@uninsubria.it](mailto:lorenzo.dominioni@uninsubria.it)

## Introduction

With the aim to contribute to the assessment of the effectiveness of chest x-ray (CXR) screening for lung cancer (LC), during the 1997-2006 period we carried out an observational study of CXR screening on a clearly defined population-based cohort. This project was coordinated by the Center for Thoracic Surgery of the University of Insubria, Varese, Italy and was funded by Non-Profit Organizations. The study was approved by the Varese Hospital and Health District Ethics Committee and was registered under the registration code: ISRCTN90639073. The study cohort, consisting of 5,815 smokers all from the Varese Province, was invited to undergo a free-of-charge programme of annual CXR screenings over a pe-

riod of 5 years, and was recruited by 50 general practitioners and physicians from a population of about 60,000 adult residents from the greater Varese provincial area. The entire invited cohort received National Health Service (NHS) usual care, with the addition of CXRs on the screening participants (21% of the invitees), according to the previously described protocol [1]. At the end of the screening programme, a total of 245 LCs were found out of the entire screening cohort (67 in participants, 178 in non-participants), of which 34 were screen-detected [1]. The LC standardized mortality ratio (SMR), for the entire screening-invited cohort, was of 0.82, indicating in the cohort a LC mortality reduction of 18%, and 38 fewer LC deaths over the study period [2]. This is a relatively small benefit, however it could save

many lives, especially given the high incidence of LC worldwide and the potentially wide applicability of CXR screening. In order to explore the NHS budget impact of a population-based LC screening intervention, it is necessary to evaluate the direct costs involved, the benefits as well as the harms. Here we describe the economic evaluation of the annual CXR screening programme we carried out in the Varese province in a general practice setting.

### Methods

We aimed to evaluate the incremental costs attributable to the programme of CXR screening for LC which we performed from July 1997 through December 2006. To this effect, over the 9.5-year duration of the screening programme we analyzed the total direct costs of CXR screening and LC management in the screening-invited cohort, and compared it with the total direct cost of LC man-

agement in a control group of patients observed in the general population of the same area in the absence of screening.

Throughout this paper the values of healthcare services, procedures and interventions were reported in Euros as of the year 2002, the central year of our screening study (tables 1-3). These values were estimated based on the 2002 Tariff of Lombardy Regional Bulletin and on data provided by the Oncology, Radiotherapy and Palliative Care Units at the Varese Ospedale di Circolo. For a more direct comparison with the most recently published literature, the incremental costs incurred with screening were expressed in terms of Euros as of 2012.

### Cost of the screening programme

Computation of direct costs attributable to the screening programme included: a) the cost of organization and administration; b) the cost of CXR

Table 1. - Cost of diagnosis and staging of lung cancer (LC)

Components of cost	Cost in Euros*
<b>Screening</b>	
CXR exam, dual projection	15.49
<b>SUB-TOTAL</b>	<b>15.49</b>
<b>Cyto-/histologic confirmation of LC</b>	
Bronchoscopy with biopsy	180.76
Cytology of sputum/pleural fluid	26.86
CT-guided fine needle aspirate and cytology	157.52
Hospital stay	624.00
<b>SUB-TOTAL</b>	<b>989.14</b>
<b>Staging of LC patient stage I-IV</b>	
Blood cells count, chemistry, tumor markers, arterial gases	117.25
EKG	11.36
CXR exam, dual projection	15.49
CT total body with contrast	482.37
Bone scintigraphy	80.57
Spirometry	23.24
Hospital stay	4,160.00
<b>SUB-TOTAL</b>	<b>4,890.28</b>
<b>Staging of patient unfit for active treatment</b>	
Blood cells count, chemistry, tumor markers, arterial gases	117.25
EKG	11.36
CXR exam, dual projection	15.49
CT total body with contrast	482.37
Hospital stay	2,496.00
<b>SUB-TOTAL</b>	<b>3,122.47</b>

CT: computed tomography. CXR: chest x-ray. EKG: electrocardiogram. LC: lung cancer.

\* Cost in Euros 2002.

Table 2. - Cost of treatment of lung cancer (LC)

Components of cost	Cost in Euros*
<b>Chest surgery</b>	
Operating room occupancy (average 3 hours)	1,165.00 - 2,331.00
Operating room materials	388.00 - 1,165.00
Hospital stay in surgical unit (average 12 days)	5,827.00
<b>SUB-TOTAL</b>	<b>7,380.00 - 9,323.00</b>
<b>Chemotherapy for LC stage III</b>	
6 cycles (Cisplatin + Gemcitabine)	4,177.00
<b>SUB-TOTAL</b>	<b>4,177.00</b>
<b>Chemotherapy for LC stage IV</b>	
3 cycles (Cisplatin + Gemcitabine)	2,089.00
<b>SUB-TOTAL</b>	<b>2,089.00</b>
<b>Palliative radiotherapy</b>	
Radiotherapy	2,405.00 - 3,385.00
<b>SUB-TOTAL</b>	<b>2,405.00 - 3,385.00</b>
<b>Radical radiotherapy</b>	
Radiotherapy (50-60 Gy)	2,405.00 - 6,974.00
<b>SUB-TOTAL</b>	<b>2,405.00 - 6,974.00</b>
<b>Chemo-Radiotherapy combined</b>	
Chemotherapy	2,089.00 - 4,177.00
Radiotherapy	2,405.00 - 6,974.00
<b>SUB-TOTAL</b>	<b>4,494.00 - 11,151.00</b>
<b>Supportive/palliative therapy</b>	
Oxygen	397.44
Drugs (analgesics, antibiotics, steroids)	699.00
Hospital stay	1,040.00
<b>SUB-TOTAL</b>	<b>2,136.00</b>
<b>Terminal phase</b>	
Cumulative cost of 1 month	1,399.00
<b>SUB-TOTAL</b>	<b>1,399.00</b>

LC: lung cancer.

\* Cost in Euros 2002.

Table 3. Cost of follow-up after treatment of lung cancer (LC)

Components of cost	Cost in Euros*
<b>First year of follow-up</b>	
3 Visits	58.00
2 CXR exam, dual projection	30.98
2 Blood cells count, chemistry, tumor markers, arterial gases	234.50
1 Chest CT with contrast	161.13
<b>SUB-TOTAL</b>	<b>484.61</b>
<b>Second year of follow-up</b>	
2 Visits	38.00
1 CXR exam, dual projection	15.49
2 Blood cells count, chemistry, tumor markers, arterial gases	234.50
1 Chest CT with contrast	161.13
<b>SUB-TOTAL</b>	<b>449.12</b>
<b>Third and subsequent years of follow-up</b>	
2 Visits	38.00
1 Blood cells count, chemistry, tumor markers, arterial gases	117.25
1 Chest CT with contrast	161.13
<b>SUB-TOTAL</b>	<b>316.38</b>

CT: computed tomography. CXR: chest x-ray. LC: lung cancer.

\* Cost in Euros 2002.

screenings; c) the cost of additional procedures prompted by false-positive tests. Moreover, we considered the direct cost of overdiagnosed LCs, which was based on the estimate that in the Mayo Lung Project approximately 5% of screen-detected LCs were overdiagnosed [3].

#### **Cost of LC management on the screening-invited cohort**

For each of the 245 LC cases that were diagnosed overall in the cohort [1], we computed all healthcare costs for LC management, from the time of diagnosis until the time of death. For subjects still alive at the end of study, the computation of costs was truncated at the study cut off, on December 31, 2006. Briefly, to calculate the total cost of each LC case in the cohort, costs related to LC diagnosis, staging, treatment and follow-up procedures (tables 1-3) that were individually incurred were included, stratified by stage, histology (non-small cell lung cancer, small cell lung cancer) and treatment (surgery, chemotherapy, radiation). To determine the price of the component services, we considered the phase of care and the frequency of cost-generating follow-up procedures for each case. For components with little variability of cost in the various different NHS facilities throughout the Varese province, the average cost was indicated; if the overall cost was considerably variable, the lowest value and the highest value were taken (tables 1-3).

#### **Cost of LC management in the control group**

As a control group we used a previously described group of 156 uninvited and unscreened LC patients diagnosed during the 2000 calendar year in the Varese district area, who possessed the necessary screening criteria [1]. Over the 9.5-year timeframe we computed the total direct cost of healthcare procedures and interventions (tables 1-3) incurred for LC management for these 156 control group patients, who received the NHS usual standard of care in the absence of screening.

#### **Results**

##### **Cost of the screening programme**

The total direct cost of the screening programme over the 9.5-year period from July 1997 through December 2006 was estimated to range from € 390,934 to € 394,042 (table 4), after adding up the cost components a), b), c), as follows:

##### *a) Organization and administration*

The general expenses incurred for the initial organization of the screening programme comprised: office supplies; printed recruitment forms and brochures; mailing of screening invitation letters; advertising of screening with posters and announcements in local newspapers, radio and TV; purchase of personal computers to store CXR readings in the 7 NHS radiologic centers collaborating in the project; dedicated software for database in the project main office. Cost of programme administration included: part-time secretary; office utilities and material supplies; staff meetings. Total cost of organization and administration over the 9.5 years was € 242,632.

Table 4. - Cost of screening programme, period July 1997 - December 2006

Components of cost	Cost in Euros*
<b>Organization and administration</b>	242,632
<b>Total cost of CXR (5,581 screens)</b>	86,450
<b>Additional procedures prompted by screening</b>	
• Chest CT with contrast (190 false positives)	30,615
• CT-guided fine needle biopsy (1 subject)	157
• Thoracoscopic lung wedge biopsy (8 subjects)*	31,080 - 34,188
<b>Total*</b>	<b>390,934 - 394,042</b>

CT: computed tomography. CXR: chest x-ray.

\* Lowest and highest value of estimated cost, in Euros 2002.

**b) CXR screens**

Total expenditure for the 5,581 screening tests performed on the screening participants (baseline, n=1,244; annual screens, n=4,337) was € 86,450.

**c) Additional procedures prompted by screening**

Uncertain or false-positive tests [1] prompted the following additional investigations: 190 chest computed tomography (CT) exams with contrast; one fine-needle aspirate cytology of lung; 8 thorascopic lung wedge resections for biopsy. The total cost of these additional procedures, none of which caused severe complications, ranged from € 61,852 to € 64,960.

**Cost of LC management in the screening-invited cohort**

The total direct cost incurred for healthcare of all LC cases diagnosed in participants and in non-participants of the invited cohort is shown in table 5, with the indication of the lowest and highest value of services. The total direct cost of all 245 LC cases of the screening-invited cohort ranged from € 2,959,155 to € 3,324,662 (table 5). The latter cost will subsequently be compared in table 5 with the total direct cost of only 243 LCs of the control group, as 2 LCs in the invited cohort were likely to have been overdiagnosed (see below).

**Overdiagnosed LCs**

As 34 LCs were screen-detected in our screening programme [1], we approximated that 2 LCs (5%) had been overdiagnosed. Accordingly during

the calculation of the incremental costs of screening, to account for overdiagnosed LCs, the total direct cost of only 243 control group LCs will be subtracted from the cost of the 245 LCs from the screening-invited cohort (see calculation in table 5).

**Total cost of screening and LC management in the screening-invited cohort**

The cost of the screening programme added to the cost of LC management of all 245 cases in the screening-invited cohort totaled between € 3,350,089 and € 3,718,704 (computation shown in table 5).

**Cost of LC management in the control group**

The mean direct cost of LC management for each patient of the control group was estimated to range from € 11,809 to € 13,361, implying a total expenditure ranging from € 2,869,615 to € 3,246,723 for the 243 LCs from the control group (table 5). The total cost of LC management was slightly lower in the control group compared to the invited cohort, as in the latter there were 2 overdiagnosed cases treated and higher number of stage I surgically treated patients (table 5).

**Incremental costs of LC management including screening**

In the invited cohort the cumulative incremental costs of LC management, including screening, was estimated to range between € 471,981 and € 480,474 over the 9.5-year study period (see calcu-

Table 5. - Lowest and highest direct cost (Euros\*) estimated for management of lung cancer (LC) cases during the 9.5 years of study (July 1997- December 2006)

	LCs of screening invited cohort (n=245)		LCs of control group (n=243) <sup>^</sup>	
	Lowest cost	Highest cost	Lowest cost	Highest cost
<b>(A): Cost of the screening programme #</b>	390,934	394,042	0,00	0,00
<b>(B): Cost of LC management</b>	2,959,155	3,324,662	2,869,615	3,246,723
<b>[(A)+(B)]: Total cost of screening and LC management</b>	3,350,089 (a)	3,718,704 (b)	2,869,615 (c)	3,246,723 (d)
<b>Incremental cost of LC management including screening</b>	480,474 (a)-(c)	471,981 (b)-(d)		
<b>Incremental cost of LC management including screening (Euros 2012)</b>	618,370	607,440		
<b>Incremental cost per one LC death averted with screening (Euros 2012) @</b>	<b>16,273</b>	<b>15,985</b>		

LC: lung cancer.

\* Costs in the table are in Euros 2002 (the central year of the study), except in the last two lines where the incremental cost incurred with screening is shown after conversion in Euros 2012 (x 1.287, based on ISTAT healthcare price index).

<sup>^</sup> Cost was calculated for 243 cases because 2 cases were estimated to be overdiagnosed (see text).

# Cost of administration, CXRs and false-positives management.

@ A total of 38 LC deaths were averted during the 9.5 years of study.



lation in table 5). After conversion based on the IS-TAT healthcare price index, this corresponds to a total of between € 607,440 and € 618,370 as of 2012 (approx. € 63,941 - € 65,092 per annum). Accordingly, the incremental costs of LC management including screening ranged between € 15,985 and € 16,273 for each of the 38 LC deaths averted in the cohort.

In conclusion, in a general population of 60,000 adults we carried out an annual CXR screening program targeted at 5,815 high-risk smokers, and found that the overall healthcare expense for LC management including screening increased approximately by € 65,000 per annum.

### Discussion

It has long been recognized that LC has better prognosis when it is incidentally detected during routine CXR examinations. LCs when incidentally diagnosed are frequently at an early stage and are resectable, meanwhile symptom-detected cases are predominantly advanced stage cases and are rarely curable [4-6]. For this reason chest radiograph, a widely accessible and relatively inexpensive examination, is intuitively appealing as a screening tool for early stage LC diagnosis in subjects with an increased risk of death from LC such as smokers and former smokers. However, the numerous randomized trials carried out to evaluate CXR screening for LC have brought only mixed results [7-10] and present important methodological weaknesses [2, 5, 7, 9, 11]. All of the randomized trials have been criticized due to a self-selection bias of volunteers [7, 12], and there still remains uncertainty regarding the value of LC screening at population level in the real world [2]. Accordingly the U.S. Preventive Services Task Force stated that the evidence provided, whether it be for or against CXR screening, is insufficient [13].

Nevertheless, several authors have set out to develop LC screening programs and cost-effectiveness models with sensitivity analyses [6, 14, 15]. These analyses are quite difficult to interpret. Models of simulated cohorts have provided highly variable estimates, ranging from highly cost-effective to non cost-effective treatment methods [14-17], and it remains uncertain whether a public healthcare system can afford the financial burden of population-based screening for LC.

In 1997 we started a population-based programme consisting of annual CXR screenings in the cohort of high-risk smokers who were identified within a general population of 60,000 adults from the Varese province. After the 9.5 year observation period we subsequently reported that within the screening-invited cohort, LC mortality had reduced by 18% [2]. At this point we analyzed the direct costs of our screening programme. For the entire cohort of 5,815 screening-invited smokers (21% of whom participated) [12], the incremental cost (as of 2012) of LC management including screening was estimated to range between € 607,440 and 618,370 (approximately € 65,000

per annum). As 38 fewer LC deaths were recorded in the invited cohort, the additional cost of screening to avoid one LC death (when compared with no screening and after accounting for over-diagnosis) was approximately € 16,000. The latter cost favourably compares with the recently estimated \$240,000 additional cost of screening with CT to avert one LC death [6], a ten-fold cost increase. Our study has limitations. First of all, cost estimates calculated in 2002 were applied to the whole period from July 1997 through December 2006. Because 2002 was the central year of our programme, it is highly unlikely that the overall cost of healthcare for all LCs in the study was markedly either under- or overestimated. Secondly, an element of cost was waived in our analysis, possibly causing screening program costs to be slightly underestimated: the screening programme main office was made available free of charge on NHS premises at the Center for Thoracic Surgery of University of Insubria, at the Varese Ospedale di Circolo. A strong feature of this study is the analytical computation based on all costs actually incurred during screening and LC management in all individual cases which occurred both within the invited cohort and the control group in the NHS setting in Varese. With emphasis of the current study being on cost, a complete cost-effectiveness assessment of the screening programme carried out on smokers remains to be done. However, the quantification of all the direct costs we incurred during our population-based CXR screening programme may be used by health policy makers to better explore the NHS budget impact and economic sustainability of LC screening.

**Acknowledgements:** This study was funded in part by Associazione PREDICA onlus, by the University of Insubria FAR1997-FAR2007 and by the Varese Lions Clubs Host and District 108 Ib-1.

We gratefully acknowledge the support and assistance provided by the Amare no-profit organization Como, Italy and by the Paola Giancola Foundation for Cancer Research Como, Italy.

### References

1. Dominioni L, Rotolo N, Mantovani W, *et al.* A population-based cohort study of chest x-ray screening in smokers: lung cancer detection findings and follow-up. *BMC Cancer* 2012; 12: 18.
2. Dominioni L, Poli A, Mantovani W, *et al.* Assessment of lung cancer mortality reduction after chest X-ray screening in smokers: a population-based cohort study in Varese, Italy. *Lung Cancer* 2013; 80: 50-4.
3. Yankelevitz DF, Kostis WJ, Henschke CI, *et al.* Over-diagnosis in chest radiographic screening for lung carcinoma: frequency. *Cancer* 2003; 97: 1271-5.
4. Guiss LW. A 5-year follow-up of roentgenographically detected lung cancer suspects. *Cancer* 1960; 13: 82-90.
5. Spiro SG. Screening for lung cancer: yet another problem. *Thorax* 2007; 62: 105-6.
6. Goulart BH, Bensink ME, Mummy DG, Ramsey SD. Lung cancer screening with low-dose computed tomography: costs, national expenditures, and cost-effectiveness. *J Natl Compr Canc Netw* 2012; 10: 267-75.
7. Humphrey LL, Teutsch S, Johnson M; U.S. Preventive Services Task Force. Lung cancer screening with sputum

- cytologic examination, chest radiography, and computed tomography: an update for the U.S. Preventive Services Task Force. *Ann Intern Med* 2004; 140: 740-53.
8. Church TR. Chest radiography as the comparison for spiral CT in the National Lung Screening Trial. *Acad Radiol* 2003; 10: 713-5.
  9. Manser R, Irving LB, Stone C, Byrnes G, Abramson M, Campbell D. Screening for lung cancer. *Cochrane Database Syst Rev* 2004; CD001991.
  10. Sox HC. Screening for lung cancer with chest radiographs. *JAMA* 2011; 306: 1916-8.
  11. Dominioni L, Poli A, Mantovani W, Rotolo N, Imperatori A. Volunteer effect and compromised randomization in the Mayo Project of screening for lung cancer. *Eur J Epidemiol* 2011; 26: 79-80.
  12. Dominioni L, Rotolo N, Poli A, *et al.* Self-selection effects in smokers attending lung cancer screening. A 9.5-year population-based cohort study in Varese, Italy. *J Thorac Oncol* 2010; 5: 428-35.
  13. U.S. Preventive Services Task Force. Lung cancer screening: Recommendation statement. *Ann Intern Med* 2004; 140: 738-9.
  14. Manser R, Dalton A, Carter R, Byrnes G, Elwood M, Campbell DA. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting. *Lung Cancer* 2005; 48: 171-85.
  15. McMahon PM, Kong CY, Bouzan C, *et al.* Cost-effectiveness of computed tomography screening for lung cancer in the United States. *J Thorac Oncol* 2011; 6: 1841-8.
  16. Mahadevia PJ, Fleisher LA, Frick KD, Eng J, Goodman SN, Powe NR. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. *JAMA* 2003; 289: 313-22.
  17. Wisnivesky JP, Mushlin AI, Sichertman N, Henschke C. The cost-effectiveness of low-dose CT screening for lung cancer: preliminary results of baseline screening. *Chest* 2003; 124: 614-21.



*Pavia - Università, Aula Magna*